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Introduction
Many common side-effects associated with CNS-active drugs 
relate to the potential for impaired psychomotor performance. 
While frequently such effects (sedation, fatigue, etc.) may be tran-
sient and readily reversible, in more severe case can result in gross 
impairment of coordination, prolonged response time, and cogni-
tive impairment.
Performance tasks have long been used to assess sensory, motor, 
and cognitive function under a variety of conditions. A number 
of techniques have been used to specifically determine the ef-
fects of drugs on these functions, however most measure only 
single performance variables. Although such tests may be valid 
and are often relied upon to indicate some degree of impairment 
or change in performance, they can be limited in their sensitivity 
and specificity [1].
Divided-attention tasks, which test multiple performance vari-
ables, provide an alternate means for testing both cognitive and 
sensorimotor impairment and may be more sensitive to drug ef-
fects when compared to single-variable performance tasks [2].
Some drugs used medicinally for which divided-attention tasks 
have been employed to evaluate side effects or adverse reactions 
include antihistamines [3-11], opioids [12-15], sedatives [16], 
stimulants [4,[17-19]] and psychotherapeutic agents [15,18,[20-
27]], among others [28-32]. However, their application with 
therapeutic drugs has been relatively limited and greater focus 
has been on validating their use in evaluating the effects of rec-
reational drugs including alcohol [18,19,[24-27],[33-59]] marijuana 
[36,52,55,56,[60-62]], and ecstasy [63].
The purpose of this study was to evaluate a computer-based 
divided-attention task as a method of objectively measuring the 
influence of centrally-active pharmacologic agents on human task 
performance. The study objectives were to: assess the ability of a 
divided-attention task to detect and differentiate the effects of a 
caffeine and diphenhydramine on human task performance; as-
sess learning and boredom effects associated with the divided-at-
tention task; and provide a basis for comparing the divided-atten-
tion task to other tests commonly used to measure drug-impaired 
performance.
Materials and Methods
Ten healthy, non-smoking, male subjects between 23–29 years of 
age (mean 25.5 years, ± 2.0) participated in the study. Subjects’ 
weights ranged between 60-90 kg (mean 76.0 kg, + 11.3) and were 
within 15% of ideal body weight. Subjects had an average daily 
dietary intake of caffeine of 298 mg/day and were excluded if they 
consumed >325 mg/day. Subjects were excluded from the study 
if they had a positive history of recreational drug abuse or con-
sumed >1 ounce/day of alcohol (190 proof equivalent). Subjects 
were determined to qualify for the study after satisfactory com-
pletion of a medical interview and documentation of corrected 
vision of 20/30 or better in both eyes. All subjects gave written 
informed consent and were paid for their participation. Prior to 
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initiation, the study protocol was reviewed and approved by the 
Committee for Protection of the Rights of Human Subjects at the 
University of North Carolina at Chapel Hill.
A placebo-controlled, randomized, crossover study design was 
employed which included a training phase and four treatment 
phases. Each treatment phase consisted of a baseline period, a 
dosing period, and a washout period. During the baseline period 
subjects were queried regarding the use of any medication dur-
ing the preceding 48 hours and the amount of sleep received the 
evening prior to the study to determine eligibility to participate 
in the study that day. During treatment phase 1 all subjects re-
ceived placebo (PLA) in single-blind fashion. Treatment phases 2 
through 4 were double-blind during which subjects received one 
of three oral treatments in random order including placebo (PLB), 
diphenhydramine 100mg (DPH), or caffeine 325mg (CAF). Sub-
jects ingested study medication at 10 AM (time 0) to avoid pos-
sible diurnal variation in performance. 
Subjects received a caffeine-free snack and lunch at standard 
times during each treatment phase. Subjects were allowed to free-
ly move about during the treatment phase but remained in the 
research unit until the current phase was completed. A washout 
period between treatments was established with a minimum of 18 
hours and a maximum of 14 days.
A battery of three tests was used to measure task performance 
including a divided-attention task, a short-term memory test, and 
visual analogue scales.
Divided-Attention Task (DAT)
This computer-based test consisted of a central display monitor, 
two peripheral numeric displays, a four-button response panel, 
and a foot pedal (Figure 1). The central monitor, which graphical-
ly simulated a speedometer, and peripheral displays were arranged 
in a pattern similar to an automobile dashboard. The response 
panel in front of the subject was positioned midway between the 
peripheral displays, and the foot pedal was placed in a comfort-
able position on the floor. This test required the subject to moni-
tor the central display, which presented digital numeric informa-
tion changing approximately each 0.5 seconds, in the central field 
of vision. The subject was given a critical value range (53-57) for 
central display information to remember while performing the 
test. When the central display presented a number outside this 
critical range, the subject was instructed to respond by pressing 
the corresponding button on the response panel. Simultaneously, 
the peripheral displays presented a default value of 4. If either the 
left or right display changed from the default value to the number 
3 the subject pressed a corresponding left or right response but-
ton. If either display changed to the number 7 the subject pressed 
the foot pedal. If either display changed to the number 5 the sub-
ject was not to respond in any manner, the purpose of which 
was to measure false-positive responses. Subjects were tested for 
two 2-minute trials at each assessment time during which they 
received approximately 180 central and peripheral stimuli changes 
per trial. The inter-stimuli interval ranged from 0.23-0.75 sec. Al-
ternate programs of stimuli were presented randomly during suc-
cessive trials to minimize the likelihood that the sequences would 
be memorized.
DAT Score = (C%/Clat) + (PL%/PLlat) + (PR%/PRlat) + 
(F%/Flat)
Scores were computed as the mean of the two trials at each assess-
ment time using the above formula, where: C% = percentage of 
correct responses to central display; Clat = latency of responses 
(msec) to central display; P% (L or R) = percentage of correct 
responses to left or right peripheral displays corrected for false-
positive responses; and Plat (L or R) = latency of responses to left 
or right peripheral displays; F% = percentage of correct responses 
with the foot pedal; and Flat = latency of foot pedal responses. 
A maximum score is not defined since theoretically scores could 
infinitely improve. However, the average scoring range is 5–40.
Short-Term Memory Test (STMT)
During each assessment with this computer-based test, six sets of 
four related words were displayed on the screen at a rate of one 
word every two seconds; a sample list appears in Table 1. At the 
end of each presentation the subject typed the words back into 
the computer in order of sequence with correct spelling. Twenty-
six alternate word sets were presented randomly on successive tri-
als to minimize memorization. Scores were computed according 
to the formula below, where: W = number of words remembered; 
X = number of words in correct sequence; Y = number of words 
misspelled; and Z = number of words that did not appear in the 
presentation. The maximum score attainable on this test is 100%.
STMT Score = [(W + X – ½Y – Z)*100]/48
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Figure 1. Graphical Representation of  Computerized Divided-Attention Task
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Visual Analogue Scales (VAS)
Subjects were asked to express their perceived present physical 
and emotional state by drawing a perpendicular mark across a set 
of 18 ungraduated 100mm lines (Figure 2). At opposing ends of 
each were pairs of contrasting adjectives and the line represented 
the entire spectrum between the adjectives with the extreme ends 
expressing absolute, and somewhere in between corresponding 
to how the subject would normally feel [64]. VAS scores were 
determined by measuring from the middle of the line to the sub-
ject’s mark and reported as + depending on whether the adjective 
closest the mark was a positive or negative response. The score 
at each assessment time is reported as a mean of all 18 individ-
ual line scores. The “interested-bored” continuum, a single line 
of the full VAS test, was used to directly measure boredom. A 
training phase was conducted to instruct individual subjects on 
how to perform each task the day before study commencement. 
Training consisted of 30 trials on the DAT in order to provide 
sufficient practice time to reach a performance plateau with a 
reference score being established using the mean of the last 20 
performance trials. A single trial with the STMT and VAS tasks 
served as training for those test procedures. During each base-
line period subjects completed two DAT trials with the mean of 
these DAT scores being recorded as the baseline score for that 
treatment phase. They also completed a STMT and VAS trial to 
establish a baseline score. During treatment phase 1 the subjects 
were tested using only DAT. The purpose of this phase was to 
allow observation of subject performance on DAT without in-
teraction of the other performance tests while under normal test 
conditions. During treatment phases 2 through 4, subjects were 
Table 1. SampleShort-TermMemoryTest
FRANCE BROWN CARROT CROW HAMMER ROSE
ITALY MAROON POTATO WREN CHISEL TULIP
SWEDEN AQUA CELERY DOVE SCREW LILY
NORWAY BURGUNDY CABBAGE PENGUIN SANDPAPER DAISY
Table 2. Divided-Attention Performance Task Scores (Mean+SD)
TIME(mins)
TREATMENT 0 30 50 70 90 120 150 180 210 240 270 300
PLA 24.9 22.8 22.7 23.1 24.4 24 23.4 23.7 22.9 24.1 23.6 22.9
Mean+SD 2.4 2.9 3.9 2.4 3.3 3.1 4 2.7 4.7 3.7 2.9 1.6
PLB 25.5 24.1 26.3 24.3 25 25.2 26.7 25.9 24.7 25.7 22.9 24
Mean+SD 2.4 2.8 3.8 2.7 4.2 3 3.5 3.9 3.5 2.9 3.1 7.1
CAF 25.6 26.1 26.3 25.4 26.8 27.1 26.8 26.1 27.3 26.3 26 26
Mean+SD 3.2 2.9 2.8 3.1 3.6 1.8 3.9 3.2 2.4 3.9 2.2 3.9
DPH 25.9 26.2 25.8 23.5 21.8 21.2 21.3 19.4 18.8 22.3 23.4 23.1
Mean+SD 2.1 2.6 3.9 2.9 2.6 3.3 4.3 6.3 3 2.5 4.1 5.6
PLA (Placebo A; Treatment Phase 1), PLB (Placebo, Treatment Phases 2–4), CAF (Caffeine 325mg), DPH (Diphenhydramine 100mg), 
SD (standard deviation)
Drowsy
Excited
Weak
Clear-Aheaded
Clumsy
Energitic
DisContended
Tranquil
QuickWitted
Relaxed
Dreamy
SkillFull
Sad
Friendly
Bored
Sociable
Elated
Outgoing
Alert
Calm
Strong
Confused
Well-Coordinated
Sluggish
Contented
Troubled
MentallySlow
Tence
Attentive
Incompetent
Happy
Hostile
Interested
Withdrawn
Depressed
Introverted
Figure 2. Visual Analogue Scales
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tested using all three tasks following the order of DAT, STMT 
and VAS. DAT and STMT testing was performed during all treat-
ment phases at 30, 50, 70, 90, 120, 150, 180, 210, 240, 270 and 
300 mins following drug administration, while VAS testing was 
performed at essentially hourly at 70, 120, 180, 240 and 300 mins.
Data Analysis
The ability of the tests to detect drug effect on task performance 
was assessed using the pharmacodynamic parameters of maximum 
change in score from baseline and time of maximum change. To 
determine whether the tests could differentiate between the ef-
fect of CAF, DPH and PLB, data was summarized at individual 
time points for each performance test using the mean + standard 
deviation. Treatment differences were evaluated for each test at 
individual time points with repeated measures analysis of vari-
ance (ANOVA) for a three period crossover study. The ANOVA 
model included the predictor variables subject, phase and treat-
ment. Type III sum of squares was used to simultaneously con-
trol for all main effects in the model at the same time. The level 
of significance (α) for differences in main effect was 0.05. Three 
pairwise treatment comparisons were also performed with the 
level of significance adjusted for multiple comparisons, control-
ling for type I error, to a value of 0.05/3 (0.017). Learning effects 
associated with DAT were evaluated at individual time points us-
ing the phase predictor variable from the ANOVA model. Bore-
dom effects associated with the testing procedures were assessed 
subjectively using the “interested-bored” continuum of the VAS 
test. Carryover effect was evaluated by adding prior treatment as 
a predictor variable to the ANOVA model in addition to subject, 
phase and treatment. The results obtained with DAT at each time 
interval were compared with those obtained with STMT and VAS 
using a nonparametric test of correlation (Spearman’s Rank Cor-
relation Coefficient).
Results
Performance on Divided-Attention Task 
DAT scores across treatment phases and times and are sum-
marized in Table 2 and represented in Figures 3 and 4. During 
PLA, PLB and CAF treatment phases no discernible pattern of 
alteration in DAT scores was observed. Following DPH treat-
ment DAT scores remained essentially unchanged during the first 
three time intervals, but then performance declined to a mean 
maximum change in DAT score of -7.1 at 210 minutes and did 
not return to baseline. There was a slow-down in the decline of 
performance at 150 mins which followed the scheduled caffeine-
free snack at 120 minutes. Pairwise comparisons of DAT scores 
summarized in Table 3 reveal a statistically significant treatment 
effect between PLB and DPH during the period of 120 to 210 
mins, and CAF and DPH during the period of 90 to 210 mins. No 
statistical differences in DAT scores between PLB and CAF treat-
ment were noted. Carryover effect influencing DAT performance 
was not evident at any time (p = 0.10).
DAT scores during the training phase are represented in Figure 5. 
Subjects began the training phase with a mean group DAT score 
of 9.9 + 3.1 (Range, 5.1–14.4). The group reference score estab-
lished as a mean of trials 21–30 was 22.4 + 2.4 (Range, 18.9–26.5). 
Subjects demonstrated a clinically significant learning effect on 
successive trials that eventually appeared to plateau by the end 
of the training phase. However, when the DAT reference score 
is compared to baseline DAT scores observed over successive 
treatment phases, a continued numerical increase can be observed 
(Figure 6) with DAT scores incrementally increasing by 19.2% 
from the training phase to the baseline of treatment phase 3. A 
review of individual scores reveals that four subjects continued to 
improve across the entire study with peak baseline performance 
being observed at the beginning of treatment phase 4; five sub-
jects had peak baseline performance in treatment phase 3 with 
subsequent decay in treatment phase 4; and one subject had peak 
performance in treatment phase 2 with decay in both successive 
treatment phases. In the majority of cases, the most substantial 
improvement was observed between the training phase and the 
first treatment phase. A statistically significant phase effect of 
DAT scores was observed at 30mins (p <0.0088) indicating ad-
ditional learning effect or potential motivation.
30
28
26
24 
22
20
18
16
14
12
10
     0       30       50       70       90     120     150      180     210    240      270     300 
D
AT
 S
co
re
(m
ea
n)
Chart Title
Figure 3. Divided-Attention Scores on PLA (Placebo) during Treatment Phase 1
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Figure 4:Divided-Attention Task Performance Scores on PLB (Placebo), CAF (Caffeine 325mg) and 
DPH (Diphenhydramine 100mg) Treatments during Treatment Phases 2–4
Table 3. Pairwise Comparisons of  Task Performance Scores
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Figure 5. Learning Effect Observed during Pre-Study Divided-Attention Task Training
PLB (Placebo, Treatment Phases 2–4), DPH (Diphenhydramine 100mg), CAF (Caffeine 325mg), DAT (Divided-attention task), VAS 
(Visual analogue scales), STMT (Short-term memory test), NS (non-significant)
TIME (mins)
TASK 0 30 50 70 90 120 150 180 210 240 270 300
PLB vs. DPH
DAT NS NS NS NS NS 0.002 0.003 0.005 0.000 NS NS NS
VAS NS - - 0.007 - 0.000 - 0.000 - 0.001 - NS
STMT NS NS NS NS NS NS NS NS NS NS NS NS
CAF vs. DPH
DAT NS NS NS NS 0.005 0.000 0.007 0.005 0.000 NS NS NS
VAS NS - - NS - 0.000 - 0.000 - 0.001 - NS
STMT NS NS NS NS NS NS NS NS NS NS NS NS
PLB vs. CAF
DAT NS NS NS NS NS NS NS NS NS NS NS NS
VAS NS - - NS - NS - NS - NS - NS
STMT NS NS NS NS NS NS NS NS NS NS NS NS
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Figure 6. Evaluation of  Continued Learning Effect on the Divided-Attention Task when the Training Phase Reference 
Score is Compared to Baseline Scores during Treatment Phases 1–4
Performance on Visual Analogue Scales
VAS scores across treatment phases and times and are summa-
rized in Table 4 and represented in Figure 7. A maximum change 
in VAS score from baseline was observed at 180 mins during 
DPH treatment and, similar to DAT, scores did not return to 
baseline. Pairwise comparisons of VAS scores summarized in 
Table 3 reveal a statistically significant treatment effect between 
PLB and DPH during the period of 70 to 240 mins, and between 
CAF and DPH during the period of 120 to 240 mins. VAS scores 
exhibited no change from baseline during PLB and CAF treat-
ments. Carryover effect influencing VAS performance was not 
evident at any time (p=0.2468). As assessment of boredom, using 
the “interested-bored” continuum as a single-line component of 
the full VAS test, revealed a slight but clinically and statistically in-
significant increase in mean boredom score from baseline to 300 
mins during each treatment. However, considerable inter-subject 
variability was also evident.
Performance on Short-Term Memory Test
STMT scores across treatment phases and times and are summa-
rized in Table 5 and represented in Figure 8. STMT scores were 
numerically higher after CAF and numerically lower after DPH. 
However, scores remained more uniform across treatments when 
compared to DAT or VAS scores with no statistical differences in 
STMT scores being detected during any treatment.
 
CorrelationbetweenPerformanceTasks 
During DPH treatment, a comparison of DAT performance with 
that of VAS revealed an inverse correlation (r = -0.32; p <0.01). 
The observed negative correlation was consistent with the scor-
ing process used in the two tests, with a decrease in DAT score 
and an increase in VAS score both reflecting a decrease in perfor-
mance. Likewise, during DPH treatment, a comparison of DAT 
performance with that of STMT revealed a statistically significant 
correlation (r = 0.33; p <0.003). During either PLB or CAF treat-
ments no correlation was observed between DAT and VAS or 
STMT performance.
Discussion
The primary objectives of the investigation were to validate the 
ability of a divided-attention task to detect (demonstrate sensitiv-
ity) and differentiate (demonstrate specificity) the effects of place-
bo, diphenhydramine and caffeine on psychomotor performance, 
and to compare divided-attention task scores with those obtained 
with other tests that are commonly used to detect drug-induced 
changes in performance.
The results show that DAT demonstrated the sensitivity needed 
to detect the depressant effects of DPH. The change in DAT 
scores appeared to inversely approximate the previously report-
TIME (mins)
TREATMENT 0 70 120 180 240 300
PLB 32.4 30 29.3 29.6 31.1 30.6
Mean + SD 9.8 11.2 8.2 9.4 10.8 11.1
CAF 30.7 29.2 28.6 28.3 29.5 27.1
Mean + SD 11.9 11.8 11 10 10 10.8
DPH 36.4 41.1 54 56 45.3 38.5
Mean + SD 13.6 14.3 14 13 12.5 15.9
Table 4.  Visual Analogue Scale Performance Task Scores (Mean + SD)
PLB (Placebo, Treatment Phases 2–4), CAF (Caffeine 325mg), DPH (Diphenhydramine 100mg), SD (standard deviation)
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Figure 7. Visual Analogue Scale Performance Scores on PLB (Placebo), CAF (Caffeine 325mg) and 
DPH (Diphenhydramine 100mg) Treatments during Treatment Phases 2–4
ed serum concentration-time curve observed after a single, oral 
dose of diphenhydramine 100mg [65]. Additionally, the time in-
terval between DPH administration and maximum decrease in 
DAT performance at 210 mins corresponds well with the time at 
which peak sedative effects are reported to occur following oral 
diphenhydramine administration (120–240 mins) [66]. Not only 
was there an apparent dose-response effect with DAT scores, but 
a time interaction was also evident which corresponded to the 
scheduled administration of a snack provided following assess-
ments at 120 mins. The subsequent delay of decline in perfor-
mance noted at 150 mins would suggest that the snack provided 
sufficient stimulus to arouse the subjects. Further, the observed 
sensitivity of DAT to depressant effects is consistent with results 
obtained in other studies using the same DAT apparatus where 
CNS depressant effects have been characterized for ethanol 
[19,[56-59]], and marijuana [56]. These results are corroborated 
by VAS scores where the subjects subjectively rated themselves as 
impaired. These results are also consistent with previous studies 
involving diphenhydramine [65,67,68]. DAT also appears to be 
associated with a degree of specificity for DPH effect because the 
performance curves obtained with DPH and CAF, when com-
pared, are both visibly and statistically different. 
While the depressant effects of DPH on DAT performance were 
demonstrable, sensitivity to the stimulant effects of CAF was 
not evident. Peak stimulant effects following a single oral dose 
of caffeine are reported to occur at approximately 60 mins [69]. 
However, the DAT performance curve obtained following treat-
ment with CAF cannot be characterized as being different from 
that observed after PLB administration. These results are similar 
to those observed with VAS, which also displayed no significant 
difference in influence of CAF and PLB treatments. The lack of 
sensitivity for stimulant effects are in contrast to previous results 
which showed that decrements in the accuracy and latency of re-
sponse produced by ethanol were significantly attenuated by dex-
troamphetamine in a dose-response fashion [19]. The contrasting 
results may be a reflection of study design, because in the present 
study each agent was singularly administered and the interaction 
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Figure 8. Short-Term Memory Test Performance Scores on PLB (Placebo), CAF (Caffeine 325mg) and 
DPH (Diphenhydramine 100mg) Treatments during Treatment Phases 2–4
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between sedative and stimulant agents was not assessed.
Alternatively, the lack of a significant stimulant effect due to CAF 
administration as compared to the magnitude of the depressant 
effect noted following DPH treatment may be explained by dif-
ferences in the magnitude of doses of the study drugs or caffeine 
tolerance. The intent in this study was to give a sufficient dose 
of each drug to insure the presence of a measurable response. 
Although the CNS effect of DPH is well known it is difficult to 
find reports of objectively measured sedation at recommended 
adult doses, and individual variability in response to the sedative 
effects of DPH precludes accurate prediction of side-effect po-
tential as 50% of the recipients of DPH in usual adult doses do 
not experience significant sedation [65].Because of this variability 
and because of the small number of subjects enrolled in the study, 
a dose twice the maximum recommended adult dose was used. 
By comparison, 325mg of caffeine is approximately equivalent 
to only two cups of brewed coffee. Even though the study con-
trolled for methylxanthine use, because subjects ingested some 
amount of caffeine on a daily basis a degree of tolerance was in-
herently present among subjects. A statistically detectable change 
in performance due to CAF may have been produced had the 
dose been proportionally higher or if a larger number of subjects 
had been enrolled. Finally, although increases in alertness and im-
provement in performance have been reported, negative results 
are also reported in the literature from studies in which caffeine 
has exhibited no effect on cognition and learning and has im-
paired fine motor coordination [69-72].
While both DAT and VAS were sensitive to and were demon-
strated to correlate during DPH treatment, STMT was not affect-
ed by any of the drugs. These findings also contrast with previous 
studies involving use of short-term memory tests [1]. However, 
given the level of memory being tested, the manner in which 
the test was administered, and some problems that were noted 
with external disruption, word-list repetition, and complex scor-
ing procedure, these results are not surprising. These limitations 
are consistent with previous reports that have utilized short-term 
memory tasks as performance testing tools.
The DAT testing procedure was noted to have significant learning 
effect as is common with tasks involving sensorimotor coordina-
tion. However, intensive training methods that were used to mini-
mize these effects appeared to be effective based on the plateau 
in DAT scores achieved during the training phase. Nonetheless, 
an analysis of baseline scores across successive treatment phases 
appeared to reveal a continued slight learning effect. Within treat-
ment phase assessment of learning was statistically significant at 
only one assessment time (30 mins). 
When boredom was assessed utilizing the “interested-bored” 
continuum of VAS, boredom ratings increased from baseline to 
300 mins during all treatments although this change was not sta-
tistically significant. Clinically, the curves for each treatment are 
indistinguishable, with a trend toward greater boredom during the 
DPH phase. By comparison, an analysis of scores obtained during 
treatment phase 1 when DAT was the only testing procedure em-
ployed reveals an immediate decrease in scores from baseline at 30 
mins which was sustained for the remainder of the phase. This is 
in contrast to the more variable DAT score obtained during PLB 
phase, during which all three tests were performed. Although it 
is difficult to determine the cause of this phenomenon, it would 
appear that sufficient performance demand was not placed on the 
subjects, perhaps representing boredom.
A number of characteristics have been described for an ideal test-
ing procedure that would reliably evaluate the effects of a CNS-
active drug on psychomotor performance. The task would allow 
for standardized test conditions, be designed for rapid administra-
tion, require minimal training of test administrators, not exhibit 
strong practice or fatigue effects during repeated administration, 
be sensitive and specific to various pharmacologic agents across 
a range of doses, correlate well with other test procedures, allow 
for efficient data acquisition, storage and analysis, be portable to 
facilitate use in field studies, and have high subject acceptance and 
be amenable for application to a wide variety of subject popula-
tions[73].
A limitation noted with the study design is that the subject popu-
lation selected may not be representative of the population who 
most frequently uses the studied medications. The small sample 
size used in this study required that a homogeneous population be 
selected and attempts were made to control a number of subject-
specific sources of variability previously identified in the litera-
ture. These included age due to reports of drug-induced changes 
in performance being more profound with increasing age [74,75], 
gender [75-77], and weight to reduce variability in response to 
administration of a fixed-dose of a drug.
Conclusions
The results of this study indicate that a divided-attention task is 
sensitive to the CNS depressant effects of diphenhydramine, and 
can differentiate those effects from the stimulant effects of caf-
feine as well as placebo. The correlation observed between the di-
vided-attention task and visual analogue scales in subjects receiv-
ing diphenhydramine provides evidence that this battery of tests 
may be complimentary and reliable as a measure of CNS depres-
sant effects with other CNS active drugs. The lack of correlation 
between these tasks in subjects taking caffeine probably reflects 
an absence of measurable effect and more studies need to be done 
Table 5. Short-Term Memory Test Performance Task Scores (Mean + SD)
PLB (Placebo, Treatment Phases 2–4), CAF (Caffeine 325mg), DPH (Diphenhydramine 100mg), SD (standard deviation)
TIME (mins)
TREATMENT 0 30 50 70 90 120 150 180 210 240 270 300
PLB 25.1 23.5 27 26.9 24.9 24.9 25.4 24.3 24.1 24.6 21.4 21.2
Mean + SD 7.1 6.4 7.2 7.2 9.1 11 7.6 8.9 9.7 8.9 6.5 8.9
CAF 26 30.7 29.7 27.6 29 25.5 30.5 26.1 25.5 26.1 25.1 27.8
Mean + SD 12 13 11 10.1 10 12.6 13.9 10.6 13.5 9.7 7.8 9.6
DPH 25.5 27.7 26.4 23.5 18.5 20.7 20 19.4 16.9 19.8 21.8 16.2
Mean + SD 11.7 9.6 8.4 9.4 6.7 5.8 10 9.7 6.9 6.7 7.3 5.8
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to validate their use with stimulants. Leaning effect can be effec-
tively managed with the divided-attention task as long as effective 
training is employed, and the testing procedure does not appear to 
be affected by or induce feelings of boredom over repeated meas-
ures. Divided-attention tasks therefore effectively meet many of 
the criteria desirable in a performance evaluation system, meas-
uring skills of attention, memory, recognition, decision making, 
and reaction time. While the results seen with this conveniently 
administered computer-based task are promising, additional stud-
ies examining the ability of DAT to detect drug-induced changes 
of performance need to be conducted, and should include other 
classes of centrally-active drugs over a range of doses. 
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